Unraveling Type 2 Diabetes: Insights into Dynamics and Dilemmas

NB: We do not resell your papers. Upon ordering, we do an original paper exclusively for you.

NB: All your data is kept safe from the public.

Table of Contents

Introduction
Analytical Issues
Ethical Issues
Economic Issue
Conclusion and Recommendations
References

Introduction

Definition

Type 2 diabetes is a chronic metabolic disorder characterized by high blood sugar levels (glucose) due to the body’s inability to utilize insulin properly. This results in insulin resistance, where the body’s cells become resistant to insulin, and the pancreas fails to produce enough insulin to compensate. Type 2 diabetes is typically associated with obesity, physical inactivity, and poor dietary habits, but genetics and other factors can also contribute (Brown et al., 2002). It is a non-curable but manageable condition that requires lifestyle changes, such as a healthy diet and exercise, and may also require medications to help regulate blood sugar levels. Failure to manage type 2 diabetes properly can lead to various complications, including cardiovascular disease, kidney damage, and nerve damage.

Affected Physiological Systems

Insulin resistance, decreased insulin production, and aberrant glucose metabolism are only a few of the pathophysiological pathways involved in the complex metabolic condition known as type 2 diabetes. Type 2 diabetes has insulin resistance as a major contributing factor. As the body’s cells lose their sensitivity to insulin, it causes a reduction in glucose uptake and an increase in glucose synthesis in the liver (Brown et al., 2002). As a result, there are elevated blood sugar levels, which can cause diabetes.

Aim of the Paper

This paper explores the analytical, cultural, ethical, and economic issues related to this global health problem. Analytically, the essay will examine the pathophysiology and epidemiology of type 2 diabetes, including the mechanisms underlying insulin resistance and impaired insulin secretion and the risk factors and prevalence. The essay will examine how culture affects the management of diabetes, including how cultural beliefs, norms, and practices influence dietary behaviors, medication compliance, and health-seeking behavior (Brown et al., 2002). The essay will take into account the moral ramifications of managing diabetes, such as the requirement for explicit consent, respect for autonomy, and consideration for different cultures in treatment choices. The essay will look at the financial implications of diabetes, including how much it costs to maintain, how it affects healthcare systems, and how it affects productivity. By addressing these concerns, the article will further knowledge of type 2 diabetes’s complicated and multidimensional nature and offer suggestions for how to avoid, manage, and manage this chronic condition.

Analytical Issues

Pathophysiology

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by hyperglycemia, insulin resistance, and impaired insulin secretion. The pathophysiology of T2DM involves multiple metabolic abnormalities that interact to promote the development and progression of the disease (Liu et al., 2015). Insulin resistance is a hallmark of T2DM and is characterized by reduced sensitivity of peripheral tissues to insulin, resulting in impaired glucose uptake and utilization. Insulin resistance arises from genetic and environmental factors, including obesity, physical inactivity, aging, and chronic inflammation. The inadequate insulin secretion in T2DM results from a progressive decline in the function of pancreatic beta cells, which are responsible for producing and releasing insulin in response to glucose. Chronic exposure to high levels of glucose, free fatty acids, and other metabolic stressors can lead to beta cell dysfunction and, ultimately, cell death, reducing the ability of the pancreas to produce and secrete insulin.

In addition to insulin resistance and impaired insulin secretion, T2DM is associated with abnormalities in glucose metabolism, lipid metabolism, and inflammation. In T2DM, glucose production by the liver is increased, leading to elevated fasting glucose levels, while glucose uptake and utilization by peripheral tissues are impaired, contributing to postprandial hyperglycemia (Liu et al., 2015). Dyslipidemia is also common in T2DM, with elevated levels of triglycerides, low-density lipoprotein cholesterol, and decreased levels of high-density lipoprotein cholesterol. Chronic inflammation is also a feature of T2DM, with high levels of inflammatory cytokines, such as interleukin-6 and tumor necrosis factor-alpha, contributing to insulin resistance and beta cell dysfunction.

Epidemiology

Type 2 diabetes (T2DM) is a global health problem affecting millions worldwide. The World Health Organization (WHO) estimates that 422 million persons had diabetes in 2014, and that number is anticipated to increase to 642 million by the year 2040. (Patel et al., 2015). The frequency of T2DM varies greatly amongst populations and nations, with low- and middle-income nations having the greatest rates. T2DM affects more than 25% of the adults in the United States in some places, including Pacific Island nations. However, in some regions, including Sub-Saharan Africa, the majority is significantly lower but growing quickly (Patel et al., 2015). Specific populations are also at higher risk for T2DM, including those with a family history of diabetes, those who are overweight or obese, those who are physically inactive, and those with specific ethnic backgrounds, such as South Asian, African, and Hispanic populations.

T2DM is also associated with significant morbidity and mortality, with an increased risk of cardiovascular disease, stroke, blindness, kidney disease, and amputation. In 2016, diabetes was estimated to have caused 1.6 million deaths worldwide, with over 75% occurring in low- and middle-income countries (Patel et al., 2015). In addition to its human toll, T2DM has a significant economic impact, with direct and indirect costs estimated to be in the hundreds of billions globally (Patel et al., 2015). These costs include expenses related to diabetes management, such as medications, monitoring, and hospitalization, as well as lost productivity due to disability and premature death.

Cultural Issues

Cultural beliefs play an essential role in type 2 diabetes self-management and treatments. They understand a person’s culture, including the part of a family, medication beliefs, social norms, and dietary habits. Issues with diabetes include understanding and addressing barriers to research, such as analyzing the impact of patents on genes related to diabetes or statutes that restrict certain types of new diabetes-related technologies through government approval (Hayward et al., 2005). Understanding cultural beliefs about diabetes is vital to helping people understand and manage their illnesses. Therefore, if a healthcare provider understands a person’s culture to anticipate the proper outcome of the patient’s medical care and their ability to understand, manage, and cope with the course of an illness.

The meaning of a diagnosis and the consequences of medical treatment will dictate the outcome of a patient’s health. British South Asians, especially the older first generation, believe God controls their diabetes. Medical groups take different medical approaches regarding the diverse cultural and ethical aspects of type 2 diabetes, depending on the specific culture or moral belief (Hayward et al., 2005). Doctors, nurses, and medical personnel distinguish between what is considered right or wrong at a given time in a given culture.

Medical ethics are concerned obligations of doctors and the healthcare team of professionals in a hospital or medical setting to the patient. Their perceptions of illness and death, beliefs about causes of disease, approaches to care, how illness and pain are faced and expressed, where patients seek help, and the types of treatment they prefer. To help people get diagnosed with type 2 diabetes, knowing their cultural beliefs about the disease is essential to teaching and educating them in their language and culture (Hayward et al., 2005). They must be educated on how to monitor blood glucose levels, the diet to follow, and the routine of exercising like seven days a week; introduce drugs that can range from pills of injectable insulin that will help them to improve the disease by incorporating cultural health beliefs. Sickness is perceived differently depending on cultural beliefs.

Another cultural issue that relates to type 2 diabetes is the role of food and diet. Certain cultures may have traditional foods high in fat, sugar, and salt, which can contribute to weight gain and increase the risk of developing type 2 diabetes. However, cultural traditions around food can also be an asset in promoting healthy eating habits (Dadbinpour et al., 2013). Healthcare providers can work with patients to identify culturally appropriate foods and recipes that are healthy and diabetes-friendly. Additionally, the perception of disease and illness can impact its diagnosis and treatment. In some cultures, diabetes may be seen as a punishment or a result of personal weakness or failure. This can lead to shame or guilt and may prevent individuals from seeking medical care or adhering to treatment regimens. Healthcare providers can address these cultural beliefs by emphasizing the role of genetics and environmental factors in developing type 2 diabetes and the importance of self-care and adherence to treatment.

Cultural issues can also affect the communication between healthcare providers and patients. Language barriers, cultural differences in nonverbal communication, and limited health literacy can all contribute to misunderstandings and barriers to care. Healthcare providers can address these issues by using trained interpreters, providing patient education materials in multiple languages, and using plain language and visual aids to explain medical concepts. Moreover, these concerns can affect the access to and availability of healthcare resources to prevent and manage type 2 diabetes (Dadbinpour et al., 2013). In some cultures, there may be stigmas or taboos around certain health conditions, preventing individuals from seeking care or disclosing their diabetes status to others. Additionally, cultural differences in healthcare practices and beliefs may affect the treatments and interventions available or acceptable to patients. Healthcare providers can address these issues by working with community leaders and organizations to promote diabetes awareness and education and tailoring care plans to meet patients’ cultural needs and preferences.

Ethical Issues

Disease Management Approach

Additionally, doctors face in managing T2DM is whether to start costly and intensive therapy with expensive human insulin to prevent future complications or to continue traditional treatment, which could lead to early complications. The use of human insulin therapy is more costly than conventional therapy, which may not be affordable for some patients. Doctors must balance the potential benefits of intensive therapy with the cost of treatment and the patient’s ability to pay for it (Sridhar & Madhu, 2002). Another ethical issue is the potential harm from starting intensive therapy too late, which may lead to irreversible complications, such as cardiovascular disease, kidney failure, or blindness. This can be a difficult decision for doctors, who must weigh the risks and benefits of intensive therapy and consider the patient’s quality of life, financial situation, and potential for adverse effects from the treatment (Sridhar & Madhu, 2002). Additionally, doctors must also consider the impact of their decisions on the patient’s autonomy and informed consent. Patients have the right to decide about their care, and doctors must provide sufficient information to make informed decisions.

Access to Care

Access to care is a significant ethical issue in managing type 2 diabetes (T2DM), particularly in low- and middle-income countries where resources for diabetes prevention and treatment are often limited. The World Health Organization estimates that more than 80% of deaths from diabetes occur in low- and middle-income countries, highlighting the need to address this issue (Sridhar & Madhu, 2002). The lack of access to care is compounded by the fact that T2DM disproportionately affects vulnerable and marginalized populations, including those living in poverty, ethnic and racial minorities, and those with limited healthcare services. This results in a significant disparity in diabetes prevention and treatment, with those most in need having the least access to care.

Addressing the issue of access to care requires a commitment to universal healthcare coverage and increasing access to diabetes prevention and treatment services for all individuals, regardless of their socioeconomic status. This includes focusing on community-based care models to deliver diabetes prevention and treatment services to underserved populations (Reasner & Defronzo, 2001). It also requires the development of sustainable healthcare financing models to ensure high-quality diabetes prevention and treatment services in low- and middle-income countries. These efforts will require significant investments in healthcare infrastructure, workforce development, technology, and partnerships between governments, the private sector, and civil society organizations. Addressing access to care is not only a moral imperative but also a public health necessity, as effective diabetes prevention and treatment can help reduce the disease’s burden and improve health outcomes for individuals and communities.

Informed Consent

Informed consent is a critical ethical issue in managing type 2 diabetes (T2DM). Patients with T2DM must be fully informed about their condition and treatment options to make informed decisions about their care. This includes providing patients with accurate and understandable information about the risks and benefits of various interventions, including lifestyle changes, medication, and surgery (Ahumada-Canale et al., 2019). Healthcare providers must ensure that patients have the necessary knowledge and skills to manage their condition effectively and are fully aware of the potential consequences of their decisions.

Informed consent is essential in T2DM research, including clinical trials of new diabetes treatments. Patients must clearly understand the purpose of the study, the potential risks and benefits, and their rights as research participants. Researchers must ensure that patients are not coerced or unduly influenced to participate in the research and that patients have the option to withdraw from the study at any time (Ahumada-Canale et al., 2019). Informed consent also requires ensuring that patients are fully aware of the implications of the research results, including any potential impact on their health outcomes.

Addressing issues related to informed consent requires clear communication between healthcare providers and patients, including ensuring patients have access to information in a language and format they can understand. This includes providing information in plain language and ensuring patients can access interpretation services if needed (Ahumada-Canale et al., 2019). Healthcare providers must also ensure that patients have the necessary knowledge and skills to manage their condition effectively and are fully aware of the potential consequences of their decisions. Addressing these issues is critical to ensuring that patients with T2DM receive the care they need to manage their condition effectively and improve their health outcomes.

Privacy and Confidentiality

Patients with T2DM must share sensitive personal information with healthcare providers, including medical history, blood sugar levels, and treatment plans. This information is critical to effectively managing T2DM, but it also requires high confidentiality to protect patient privacy (Ahumada-Canale et al., 2019). Patients must be confident that their health information will be kept confidential and used only for their care. Maintaining patient privacy and confidentiality requires adherence to strict data privacy and protection policies. This includes measures such as encryption of electronic health records, secure storage of physical health records, and ensuring that only authorized individuals have access to patient health information (Ahumada-Canale et al., 2019). Healthcare providers must also ensure that patients are aware of their rights related to their health information and how their data will be used. This includes obtaining patient consent for collecting, using, and disclosing their health information and providing patients with access to their health records.

In addition to ensuring patient privacy and confidentiality, healthcare providers must also navigate the tension between privacy and public health. In some cases, public health considerations may require the disclosure of patient health information to public health authorities, such as in the case of a disease outbreak (Ahumada-Canale et al., 2019). Healthcare providers must carefully balance these competing concerns and ensure that patient health information is disclosed following relevant laws and regulations and with the patient’s consent whenever possible. By maintaining strict data privacy and protection policies and balancing the need for privacy with public health concerns, healthcare providers can ensure that patients with T2DM receive high-quality care while protecting their privacy rights.

Equity

Despite advances in diabetes prevention and treatment, there are significant disparities in access to care, quality of care, and health outcomes for individuals with T2DM, particularly in low- and middle-income countries and marginalized populations. These disparities are often related to social determinants of health, including poverty, racism, and lack of access to education and healthcare services (Marceau et al., 2021). Addressing these disparities requires a commitment to social justice and ensuring all individuals have access to high-quality diabetes prevention and treatment services, regardless of socioeconomic status, race, ethnicity, or other demographic factors.

One of the significant ethical challenges related to equity in T2DM management is ensuring that all individuals have access to diabetes prevention and treatment services. This includes addressing disparities in access to healthcare services and resources, particularly in low- and middle-income countries where resources for diabetes prevention and treatment are often limited. It also includes addressing disparities in access to information and education about T2DM prevention and management, particularly in marginalized communities with limited health information and resources (Marceau et al., 2021). Addressing these disparities requires a commitment to universal healthcare coverage and increasing access to diabetes prevention and treatment services for all individuals, regardless of their socioeconomic status or other demographic factors.

Another ethical issue related to equity in T2DM management is ensuring that all individuals have access to high-quality diabetes prevention and treatment services. This includes addressing disparities in the quality of care received by individuals with T2DM, particularly in marginalized communities with limited access to healthcare services or lower-quality healthcare services (Lundqvist et al., 2014). It also includes addressing disparities in health outcomes related to T2DM, such as complications and mortality rates, particularly in vulnerable and marginalized populations. Addressing these disparities requires a commitment to improving the quality of care delivered to individuals with T2DM, ensuring that healthcare providers have the necessary training and resources to provide high-quality care.

Economic Issue

Cost of Treatment

The cost of treating Type 2 diabetes mellitus (T2DM) is one of the most significant economic issues associated with the condition. T2DM is a chronic disease that requires ongoing management, including regular medical check-ups, lifestyle modifications, and medications. The cost of these treatments can be substantial and a significant burden for individuals with T2DM, particularly those in low-income households (Lundqvist et al., 2014). The cost of diabetes medications and supplies, including insulin, blood glucose meters, test strips, and lancets, can be prohibitively expensive for some individuals, resulting in reduced access to care and poor health outcomes.

In addition to the direct costs of diabetes treatment, the condition is also associated with indirect costs, such as lost productivity and reduced economic opportunities. People with T2DM may need time off work to attend medical appointments or manage their symptoms, leading to reduced productivity and lost income (Basu & Sharma, 2018). The financial burden of diabetes can also result in reduced economic opportunities, particularly for people in low-income households who may not have the financial resources to invest in education and training or start their businesses. As a result, T2DM can exacerbate economic inequality, making it more challenging for people to break out of the cycle of poverty and achieve financial independence.

Reduced Productivity

Reduced productivity is a significant economic issue related to type 2 diabetes mellitus (T2DM) that can have many consequences for individuals, employers, and the economy. T2DM is associated with complications such as neuropathy, retinopathy, and cardiovascular disease, which can impact an individual’s ability to work and reduce productivity (Basu & Sharma, 2018). Neuropathy can cause numbness, tingling, and pain in the hands and feet, making it difficult to perform tasks requiring fine motor skills (Harrison et al., 2003). Retinopathy can cause vision loss, making it difficult to read or perform tasks requiring visual acuity. Cardiovascular disease can cause fatigue and shortness of breath, limiting an individual’s ability to perform physical tasks.

Reduced productivity can have significant economic consequences for individuals and employers. Individuals with T2DM may need to take time off work for medical appointments or to manage their symptoms. Employers may need to make accommodations for employees with T2DM, such as providing flexible work hours or modifying job duties, which can result in increased costs and reduced productivity (Haga, 2009). Reduced productivity can also impact the economy as a whole, leading to reduced economic growth and increased economic inequality.

Increased Health Costs

T2DM is a chronic condition that requires ongoing management and treatment. The cost of treatment for individuals with T2DM can be a significant financial burden, particularly for those in low-income households. Additionally, with blood glucose monitoring supplies, and medical appointments, T2DM is associated with a range of complications that require medical intervention, such as cardiovascular disease, neuropathy, and kidney disease (Haga, 2009). These complications can increase healthcare costs significantly, particularly in the long term. For example, individuals with T2DM are more likely to require hospitalization, which can be expensive and result in lost income for the individual and their family.

Moreover, healthcare systems face increased healthcare costs due to the rising prevalence of T2DM. In many countries, T2DM is one of the leading causes of morbidity and mortality, and healthcare systems are struggling to cope with the demand for diabetes prevention and treatment services. The cost of managing diabetes and its associated complications significantly strains healthcare systems, particularly in low- and middle-income countries, where resources are limited (Patel et al., 2015). As a result, governments and healthcare providers are faced with the challenge of providing high-quality diabetes prevention and treatment services while also managing the associated costs. This requires a multi-pronged approach that addresses the direct costs of T2DM management and the underlying socioeconomic factors contributing to the disease’s development and progression.

Economic Burden on Healthcare Systems

The increasing prevalence of T2DM globally has significantly strained healthcare systems, resulting in an economic burden. The rising number of individuals with T2DM puts pressure on healthcare facilities, leading to overcrowding, longer wait times, and increased demand for services. This expanded demand results in the need for additional resources, such as personnel, equipment, and infrastructure, which can be costly for healthcare systems (Patel et al., 2015). Moreover, managing T2DM involves various services requiring significant resources, including medical consultations, diagnostic tests, medications, and specialist care.

The economic burden on healthcare systems is also evident in the long-term costs of managing T2DM complications. For example, diabetes-related complications, such as kidney disease, retinopathy, and cardiovascular disease, require ongoing management and can result in costly medical procedures, including dialysis, transplantations, and surgeries (Harrison et al., 2003). The high costs of treating these complications can significantly burden healthcare systems, particularly in low- and middle-income countries, where resources are often limited (Patel et al., 2015). In addition, the burden of T2DM extends beyond the healthcare system, impacting individuals, families, and communities. Thus, it is crucial to develop strategies that address the economic burden of T2DM on healthcare systems and society.

Inequitable Access to Care

Inequitable access to care is a significant economic issue related to type 2 diabetes (T2DM) that affects many individuals in low-income households and marginalized populations. This issue can result in reduced access to necessary medications, medical care, and diabetes prevention services, leading to poor health outcomes and increased healthcare costs in the long term (Patel et al., 2015). There are various reasons for inequitable access to care, including socioeconomic factors, cultural beliefs, and systemic barriers to healthcare services.

Socioeconomic factors, such as poverty and low educational attainment, can limit access to healthcare services, including diabetes prevention and treatment services. Individuals from low-income households may lack the financial resources to pay for medical care and diabetes medications, resulting in reduced access to necessary care (Patel et al., 2015). Additionally, individuals with low levels of education may lack the knowledge and skills required to manage their diabetes effectively, leading to poor health outcomes and increased healthcare costs.

Conclusion and Recommendations

Summary

Type 2 diabetes is a severe global health problem that requires a multidisciplinary approach to prevent and manage. The pathophysiology of type 2 diabetes involves insulin resistance, impaired insulin secretion, and abnormal glucose metabolism, leading to high blood glucose levels and various complications. The essay has explored the analytical, cultural, ethical, and economic issues related to type 2 diabetes. Analytically, the paper has examined the disease’s underlying mechanisms and risk factors. Culturally, the essay has highlighted the impact of cultural beliefs, norms, and practices on diabetes management. Ethically, the essay has considered the ethical implications of diabetes management, emphasizing the importance of informed consent, patient autonomy, and cultural diversity in treatment decision-making. Economically, the essay has discussed the economic burden of diabetes, including the cost of management and the impact on healthcare systems and productivity.

Recommendations

In light of the analytical, cultural, ethical, and economic issues related to type 2 diabetes, it is imperative to take a multidisciplinary approach to prevention, management, and treatment. To start, healthcare providers should prioritize education and prevention efforts, including public health campaigns that promote healthy lifestyles and early screening and detection of the disease. This can be achieved through collaborations between healthcare providers, public health professionals, community organizations, and policymakers. In addition, healthcare providers should tailor treatment plans to individual patients’ needs and cultural backgrounds, considering factors such as medication beliefs, social norms, and dietary habits. This requires a patient-centered approach that respects patients’ autonomy, promotes shared decision-making, and emphasizes the importance of informed consent. Healthcare providers should also prioritize equity in access to care, ensuring all patients have equal access to quality care regardless of their socioeconomic status or geographic location.

References

Ahumada-Canale, A., Quirland, C., Martinez-Mardones, F. J., Plaza-Plaza, J. C., Benrimoj, S., & Garcia-Cardenas, V. (2019). Economic evaluations of pharmacist-led medication review in outpatients with hypertension, type 2 diabetes mellitus, and dyslipidemia: a systematic review. The European Journal of Health Economics, 20(7), 1103-1116. Web.

Basu, S., & Sharma, N. (2018). Under-recognized ethical dilemmas of diabetes care in resource-poor settings. Indian journal of medical ethics, 3(4), 324–326. Web.

Brown, S. A., Garcia, A. A., Kouzekanani, K., & Hanis, C. L. (2002). Culturally competent diabetes self-management education for Mexican Americans: the Starr County border health initiative. Diabetes Care, 25(2), 259-268. Web.

Dadbinpour, A., Sheikhha, M. H., Darbouy, M., & Afkhami-Ardekani, M. (2013). Investigating gstt1 and gstm1 null genotype as the risk factor of diabetes type 2 retinopathy. Journal of Diabetes & Metabolic Disorders, 12(1). Web.

Haga S. B. (2009). Ethical issues of predictive genetic testing for diabetes. Journal of diabetes science and technology, 3(4), 781–788. Web.

Harrison, T. A., Hindorff, L. A., Kim, H., Wines, R. C., Bowen, D. J., McGrath, B. B., & Edwards, K. L. (2003). Family history of diabetes as a potential public health tool. American Journal of Preventive Medicine, 24(2), 152-159. Web.

Hayward, R. A., Cowan, C., Giri, V., Lawrence, M. G., & Makki, F. (2005). Causes of preventable visual loss in type 2 diabetes mellitus. Journal of General Internal Medicine, 20(5), 467–469. Web.

Liu, X.-ming, Liu, Y.-jian, Zhan, J., & He, Q.-qiang. (2015). Overweight, obesity and risk of all-cause and cardiovascular mortality in patients with type 2 diabetes mellitus: a dose-response meta-analysis of prospective cohort studies. European Journal of Epidemiology, 30(1), 35–45. Web.

Lundqvist, A., Katarina, S. C., Johansen, P., Andersson, E., & Willis, M. (2014). Validation of the IHE Cohort Model of Type 2 Diabetes and the Impact of Choice of Macrovascular Risk Equations. PLoS One, 9(10) Web.

Marceau, L., McKinlay, J., Shackelton, R., & Link, C. (2011). The relative contribution of patient, provider, and organizational influences to the appropriate diagnosis and management of diabetes mellitus. Journal of Evaluation in Clinical Practice, 17(6), 1122–1128. Web.

Patel, N. R., Chew-Graham, C., Bundy, C., Kennedy, A., Blickem, C., & Reeves, D. (2015). Illness beliefs and the sociocultural context of diabetes self-management in British South Asians: a mixed methods study. BMC Family Practice, 16(7), 58. Web.

Reasner, C. A., & Defronzo, R. A. (2001). Treatment of type 2 diabetes mellitus: A rational approach based on its pathophysiology. American Family Physician, 63(9), 1687-8, 1691-2, 1694. Web.

Sridhar, G. R., & Madhu, K. (2002). Psychosocial and cultural issues in diabetes mellitus. Current Science, 83(12), 1556–1564. Web.

Click Here To Order Now!